The Download: a secretive antiaging drug and joining virtual power plants

A biotechnology startup, Generation Lab, announced the development of a compound it says can “re‑juvenate” human blood, a claim that has drawn attention from the longevity research community. The company, highlighted in today’s edition of *The Download* newsletter, asserts that the drug reverses age‑related changes in circulating blood cells, potentially extending healthspan and reducing the incidence of age‑associated diseases. According to the startup’s press release, pre‑clinical studies in animal models demonstrated improvements in vascular function and immune response after treatment, and the firm plans to initiate early‑phase human trials later this year. The announcement was reported by science journalist Antonio Regalado, who noted that the news positioned him as a “longevity influencer” within the emerging field of anti‑aging therapeutics.

Generation Lab’s approach builds on earlier research into parabiosis and blood‑borne factors that influence aging, aiming to isolate and replicate the beneficial components in a pharmaceutical format. The company has secured seed funding from venture capital firms focused on health technology, though it has not disclosed detailed financial terms or the identities of all investors. Regulatory filings indicate that the upcoming clinical program will evaluate safety, dosage, and biomarkers of blood rejuvenation in a small cohort of older adults. If successful, the drug could represent a novel intervention in the growing market for age‑defying treatments, pending further validation and approval by health authorities.